

Phyllis J Kanki

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9450302/publications.pdf>

Version: 2024-02-01

96
papers

2,450
citations

218677

26
h-index

223800

46
g-index

98
all docs

98
docs citations

98
times ranked

2800
citing authors

#	ARTICLE	IF	CITATIONS
1	Lower Human Immunodeficiency Virus (HIV) Type 2 Viral Load Reflects the Difference in Pathogenicity of HIV-1 and HIV-2. <i>Journal of Infectious Diseases</i> , 1999, 180, 1116-1121.	4.0	215
2	Natural protection against HIV-1 infection provided by HIV-2. <i>Science</i> , 1995, 268, 1612-1615.	12.6	210
3	Low Plasma Human Immunodeficiency Virus Type 2 Viral Load Is Independent of Proviral Load: Low Virus Production In Vivo. <i>Journal of Virology</i> , 2000, 74, 1554-1557.	3.4	136
4	High Levels of Tumor Necrosis Factor- α and Interleukin-1 β in Bacterial Vaginosis May Increase Susceptibility to Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2000, 182, 467-473.	4.0	128
5	Immunologic Criteria Are Poor Predictors of Virologic Outcome: Implications for HIV Treatment Monitoring in Resource-Limited Settings. <i>Clinical Infectious Diseases</i> , 2011, 53, 1283-1290.	5.8	121
6	Direct Evidence of Lower Viral Replication Rates In Vivo in Human Immunodeficiency Virus Type 2 (HIV-2) Infection than in HIV-1 Infection. <i>Journal of Virology</i> , 2007, 81, 5325-5330.	3.4	103
7	New human and simian HIV-related retroviruses possess functional transactivator (tat) gene. <i>Nature</i> , 1987, 328, 548-550.	27.8	101
8	Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. <i>Statistics in Medicine</i> , 2003, 22, 573-593.	1.6	98
9	Cellular Immunity to Human Immunodeficiency Virus Type 1 (HIV-1) Clades: Relevance to HIV-1 Vaccine Trials in Uganda. <i>Journal of Infectious Diseases</i> , 2000, 182, 1350-1356.	4.0	67
10	Management of HIV-1 Infection With a Combination of Nevirapine, Stavudine, and Lamivudine. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2005, 40, 65-69.	2.1	55
11	Reported Barriers to Healthcare Access and Service Disruptions Caused by COVID-19 in Burkina Faso, Ethiopia, and Nigeria: A Telephone Survey. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 323-330.	1.4	53
12	Scale-up of networked HIV treatment in Nigeria: Creation of an integrated electronic medical records system. <i>International Journal of Medical Informatics</i> , 2015, 84, 58-68.	3.3	50
13	Continued Transmission of Zika Virus in Humans in West Africa, 1992-2016. <i>Journal of Infectious Diseases</i> , 2017, 215, 1546-1550.	4.0	50
14	Highly Active Antiretroviral Therapy and Viral Response in HIV Type 2 Infection. <i>Clinical Infectious Diseases</i> , 2004, 38, 1771-1779.	5.8	48
15	Comparison of Heterologous Neutralizing Antibody Responses of Human Immunodeficiency Virus Type 1 (HIV-1)- and HIV-2-Infected Senegalese Patients: Distinct Patterns of Breadth and Magnitude Distinguish HIV-1 and HIV-2 Infections. <i>Journal of Virology</i> , 2007, 81, 5331-5338.	3.4	48
16	Genomic Sites of Human Immunodeficiency Virus Type 2 (HIV-2) Integration: Similarities to HIV-1 In Vitro and Possible Differences In Vivo. <i>Journal of Virology</i> , 2006, 80, 7316-7321.	3.4	43
17	Time-Dependent Predictors of Loss to Follow-Up in a Large HIV Treatment Cohort in Nigeria. <i>Open Forum Infectious Diseases</i> , 2014, 1, ofu055.	0.9	42
18	Long-Term Inpatient Viral Evolution during HIV-2 Infection. <i>Journal of Infectious Diseases</i> , 2007, 195, 726-733.	4.0	41

#	ARTICLE	IF	CITATIONS
19	Rates and impact of hepatitis on human immunodeficiency virus infection in a large African cohort. <i>World Journal of Gastroenterology</i> , 2013, 19, 1602.	3.3	38
20	Clinical and Genotypic Findings in HIV-Infected Patients With the K65R Mutation Failing First-Line Antiretroviral Therapy in Nigeria. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, 228-234.	2.1	36
21	Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals. <i>Vaccine</i> , 2001, 20, 905-913.	3.8	35
22	Inpatient Diversity and Its Correlation with Viral Setpoint in Human Immunodeficiency Virus Type 1 CRF02_AG-IbNG Infection. <i>Journal of Virology</i> , 2002, 76, 10745-10755.	3.4	35
23	Trained Community Volunteers Improve Tuberculosis Knowledge and Attitudes Among Adults in a Periurban Community in Southwest Nigeria. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 625-632.	1.4	32
24	Nucleoside Reverse Transcriptase Inhibitor Resistance Mutations Associated with First-Line Stavudine-Containing Antiretroviral Therapy: Programmatic Implications for Countries Phasing Out Stavudine. <i>Journal of Infectious Diseases</i> , 2013, 207, S70-S77.	4.0	30
25	Sustained Specific and Cross-Reactive T Cell Responses to Zika and Dengue Virus NS3 in West Africa. <i>Journal of Virology</i> , 2018, 92, .	3.4	30
26	Viral Dynamics of Primary HIV-1 Infection in Senegal, West Africa. <i>Journal of Infectious Diseases</i> , 2005, 191, 1460-1467.	4.0	29
27	Distinct Profile of T Cell Activation in HIV Type 2 Compared to HIV Type 1 Infection: Differential Mechanism for Immunoprotection. <i>AIDS Research and Human Retroviruses</i> , 2005, 21, 791-798.	1.1	27
28	Genetic Determinants of Drug-Resistant Tuberculosis among HIV-Infected Patients in Nigeria. <i>Journal of Clinical Microbiology</i> , 2012, 50, 2905-2909.	3.9	25
29	Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv154.	0.9	23
30	Long-Term Outcomes on Antiretroviral Therapy in a Large Scale-Up Program in Nigeria. <i>PLoS ONE</i> , 2016, 11, e0164030.	2.5	23
31	Antiretroviral Therapy-associated Adverse Drug Reactions and their Effects on Virologic Failure- A Retrospective Cohort Study in Nigeria. <i>Current HIV Research</i> , 2019, 16, 436-446.	0.5	22
32	Longitudinal evaluation of adherence, retention, and transition patterns of adolescents living with HIV in Nigeria. <i>PLoS ONE</i> , 2020, 15, e0236801.	2.5	20
33	Retention in Differentiated Care: Multiple Measures Analysis for a Decentralized HIV Care and Treatment Program in North Central Nigeria. <i>Journal of AIDS & Clinical Research</i> , 2018, 09, .	0.5	19
34	Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz. <i>Germs</i> , 2015, 5, 83-91.	1.3	19
35	Robust HIV Type 2 Cellular Immune Response Measured by a Modified Anthrax Toxin-Based Enzyme-Linked Immunospot Assay. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 1257-1264.	1.1	18
36	Tuberculosis After One Year of Combination Antiretroviral Therapy in Nigeria: A Retrospective Cohort Study. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 931-937.	1.1	16

#	ARTICLE	IF	CITATIONS
37	Quantifying an Adherence Path-Specific Effect of Antiretroviral Therapy in the Nigeria PEPFAR Program. <i>Journal of the American Statistical Association</i> , 2017, 112, 1443-1452.	3.1	16
38	Sexual dysfunction and its determinants among women infected with HIV. <i>International Journal of Gynecology and Obstetrics</i> , 2017, 137, 301-308.	2.3	15
39	The Absence of Anti-HIV-1 Tat Antibodies Is Associated with Risk of Disease Progression in HIV-1 Infection. <i>Journal of Infectious Diseases</i> , 2006, 194, 760-763.	4.0	14
40	Dyslipidemia in ART-Naive HIV-Infected Persons in Nigeria—Implications for Care. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 355-359.	1.5	14
41	The role of point-of-care viral load monitoring in achieving the target of 90% suppression in HIV-infected patients in Nigeria: study protocol for a randomized controlled trial. <i>BMC Infectious Diseases</i> , 2019, 19, 368.	2.9	14
42	Characterisation of HIV-1 Molecular Epidemiology in Nigeria: Origin, Diversity, Demography and Geographic Spread. <i>Scientific Reports</i> , 2020, 10, 3468.	3.3	14
43	In well-differentiated primary human bronchial epithelial cells, TGF- β 1 and TGF- β 2 induce expression of furin. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L246-L253.	2.9	14
44	Drug resistance patterns following pharmacy stock shortage in Nigerian Antiretroviral Treatment Program. <i>AIDS Research and Therapy</i> , 2017, 14, 58.	1.7	13
45	Impact of Hepatitis C Virus on HIV Response to Antiretroviral Therapy in Nigeria. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 62, 204-207.	2.1	12
46	Superior Effectiveness of Zidovudine Compared With Tenofovir When Combined With Nevirapine-based Antiretroviral Therapy in a Large Nigerian Cohort. <i>Clinical Infectious Diseases</i> , 2016, 62, civ928.	5.8	12
47	Treatment Outcomes Among Older Human Immunodeficiency Virus-Infected Adults in Nigeria. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx031.	0.9	12
48	Building laboratory capacity to support HIV care in Nigeria: Harvard/APIN PEPFAR, 2004–2012. <i>African Journal of Laboratory Medicine</i> , 2015, 4, .	0.6	12
49	Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and Other PrEP Modalities among Sexual Minority Men in Nigeria, Africa. <i>AIDS and Behavior</i> , 2022, 26, 2363-2375.	2.7	12
50	Status of HIV-infected patients classified as lost to follow up from a large antiretroviral program in southwest Nigeria. <i>PLoS ONE</i> , 2019, 14, e0219903.	2.5	11
51	Patterns and Predictors of First-Line Antiretroviral Therapy Modification in HIV-1-Infected Adults in a Large Urban Outpatient Cohort in Nigeria. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 348-354.	1.5	10
52	T Cell Responses to Nonstructural Protein 3 Distinguish Infections by Dengue and Zika Viruses. <i>MBio</i> , 2018, 9, .	4.1	10
53	High-risk human papilloma virus and cervical abnormalities in HIV-infected women with normal cervical cytology. <i>Infectious Agents and Cancer</i> , 2014, 9, 36.	2.6	9
54	Feasibility and acceptability of early infant screening for sickle cell disease in Lagos, Nigeria—A pilot study. <i>PLoS ONE</i> , 2020, 15, e0242861.	2.5	9

#	ARTICLE	IF	CITATIONS
55	On Partial Identification of the Natural Indirect Effect. <i>Journal of Causal Inference</i> , 2017, 5, .	1.2	8
56	Effects of selenium supplementation on pregnancy outcomes and disease progression in HIV-infected pregnant women in Lagos: A randomized controlled trial. <i>International Journal of Gynecology and Obstetrics</i> , 2021, 153, 533-541.	2.3	8
57	Treatment Discontinuation in Adult HIV-Infected Patients on First-Line Antiretroviral Therapy in Nigeria. <i>Current HIV Research</i> , 2015, 13, 184-192.	0.5	8
58	Clinical and Immunological Profile of Pediatric HIV Infection in Ibadan, Nigeria. <i>Journal of the International Association of Providers of AIDS Care</i> , 2011, 10, 49-53.	1.2	7
59	Predictors of Mortality in a Clinic Cohort of HIV-1 Infected Children Initiated on Antiretroviral Therapy in Jos, Nigeria. <i>Journal of AIDS & Clinical Research</i> , 2014, 5, .	0.5	7
60	Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2707-2715.	3.0	7
61	Patterns of Adherence and Loss to Follow-Up in Pediatric Patients on ART in Nigeria. <i>Current HIV Research</i> , 2015, 13, 210-218.	0.5	7
62	Omnibus Tests for Comparison of Competing Risks with Adjustment for Covariate Effects. <i>Biometrics</i> , 2001, 57, 818-828.	1.4	6
63	Scaling Up HIV Treatment and Prevention Through National Responses and Innovative Leadership. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, S27-S30.	2.1	6
64	Effects of selenium supplementation on pregnancy outcome and disease progression in HIV-infected pregnant women in Lagos, Nigeria. <i>Medicine (United States)</i> , 2019, 98, e12735.	1.0	6
65	Human Immunodeficiency Virus Type 2 (HIV-2). , 2004, , 223-253.		6
66	Treatment Outcomes in a Decentralized Antiretroviral Therapy Program: A Comparison of Two Levels of Care in North Central Nigeria. <i>AIDS Research and Treatment</i> , 2014, 2014, 1-10.	0.7	5
67	Implication of First-Line Antiretroviral Therapy Choice on Second-Line Options. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx233.	0.9	5
68	Distinct Pattern of Thymidine Analogue Mutations with K65R in Patients Failing Tenofovir-Based Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 228-233.	1.1	5
69	A modified anthrax toxin-based enzyme-linked immunospot assay reveals robust T cell responses in symptomatic and asymptomatic Ebola virus exposed individuals. <i>PLoS Neglected Tropical Diseases</i> , 2018, 12, e0006530.	3.0	5
70	The protective effect of HIV-2 infection. <i>Aids</i> , 2014, 28, 1065-1067.	2.2	4
71	Association between HIV-1 subtype and drug resistance in Nigerian infants. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 172-176.	3.0	4
72	Derangement of protein S and C4b-binding protein levels as acquired thrombophilia in HIV-infected adult Nigerians. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1253.	0.9	4

#	ARTICLE	IF	CITATIONS
73	Prevalence of and risk factors for pulmonary tuberculosis among newly diagnosed HIV-1 infected Nigerian children. <i>Germes</i> , 2016, 6, 21-28.	1.3	4
74	Comparative incidence of adverse drug reaction during the first and subsequent year of antiretroviral therapy in a Nigerian HIV infected cohort. <i>African Health Sciences</i> , 2021, 21, 1027-1039.	0.7	3
75	A preprogram appraisal of factors influencing research productivity among faculty at college of medicine, University of Lagos. <i>Annals of African Medicine</i> , 2020, 19, 124.	0.5	3
76	Association of Bacterial vaginosis and other Sexually Transmitted Infections with HIV among pregnant women in Nigeria. <i>African Journal of Medicine and Medical Sciences</i> , 2014, 43, 23-28.	0.2	3
77	The impact of HIV-1 subtypes on virologic and immunologic treatment outcomes at the Lagos University Teaching Hospital: A longitudinal evaluation. <i>PLoS ONE</i> , 2020, 15, e0238027.	2.5	2
78	Study of congenital heart defects among neonates in Jos, Nigeria: prevalence and spectrum. <i>Cardiovascular Journal of Africa</i> , 2021, 32, 23-29.	0.4	2
79	Subtype-specific differences in Gag-protease replication capacity of HIV-1 isolates from East and West Africa. <i>Retrovirology</i> , 2021, 18, 11.	2.0	2
80	Biology of Human Immunodeficiency Virus Type 2 (HIV-2). , 2002, , 74-103.		1
81	Monitoring Viral Load. , 2002, , 173-185.		1
82	Undetectable proviral deoxyribonucleic acid in an adolescent perinatally infected with human immunodeficiency virus-1C and on long-term antiretroviral therapy resulted in viral rebound following antiretroviral therapy termination. <i>Medicine (United States)</i> , 2019, 98, e18014.	1.0	1
83	Detection of Inducible Replication-Competent HIV-1 Subtype C Provirus Despite Long-Term Antiretroviral Treatment in Perinatally Infected Adolescents in Botswana. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 16-23.	1.1	1
84	Standardization of Aspergillus IgG diagnostic cutoff in Nigerians. <i>Therapeutic Advances in Infectious Disease</i> , 2021, 8, 204993612110501.	1.8	1
85	Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 710-717.	3.0	1
86	Factors associated with early menopause among women in Nigeria. <i>Journal of Virus Eradication</i> , 2017, 3, 145-151.	0.5	1
87	Reply to Valadas and Antunes. <i>Clinical Infectious Diseases</i> , 2004, 39, 1554-1554.	5.8	0
88	Virologic and Biologic Features of Human Immunodeficiency Virus Type 2 (HIV-2). , 2004, , 131-145.		0
89	Editorial (Thematic Issue: Programmatic Evaluation of HIV Prevention and Treatment in Nigeria). <i>Current HIV Research</i> , 2015, 13, 174-175.	0.5	0
90	Low levels of HIV-1 drug resistance mutations in patients who achieved viral re-suppression without regimen switch: a retrospective study. <i>BMC Microbiology</i> , 2020, 20, 17.	3.3	0

#	ARTICLE	IF	CITATIONS
91	HIV-2: Lessons from the Dakar Cohort. , 2013, , 1-17.		0
92	HIV-2: Lessons from the Dakar Cohort. , 2018, , 978-993.		0
93	Title is missing!. , 2020, 15, e0242861.		0
94	Title is missing!. , 2020, 15, e0242861.		0
95	Title is missing!. , 2020, 15, e0242861.		0
96	Title is missing!. , 2020, 15, e0242861.		0